Oncolytic H-1PV, whose capacity to selectively kill glioma-derived cells through a cathepsin-mediated mechanism was demonstrated in vitro (Di Piazza et al., 2007), is believed to represent a promising therapeutic alternative. The gene discussed is CTSS; the disease is glioma.